Trailing Twelve Months Revenue Growth: Rapport Corp (RAPP)

Graphic logo of Rapport Corp (RAPP)

The trailing four-quarter revenue growth rate for Rapport Therapeutics, Inc. (RAPP) reflects sales dynamics where the metric value stands at 0.00. AI implementation and bioreactor automation are accelerating the development of neuropreparations, although final tests still require scientist involvement. A stable cash reserve supports the development of receptor platforms, while the capitalization of Rapport Therapeutics, Inc. (RAPP) depends exclusively on clinical trial outcomes, ignoring macroeconomic factors.

Rapport Therapeutics, Inc. (RAPP): Revenue Growth YoY (Last 12 Months) from 11/23/2025 to 11/18/2026

rapportrx.com (RAPP) - metric breakdowns and financial figures

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Analysis of all company metrics:Rapport Corp, RAPP
Brand item of Rapport Therapeutics, Inc.

This indicator measures the growth dynamics of rolling annual revenue, eliminating quarterly gaps to provide a real-time assessment of operational activity. By analyzing the YoY revenue growth trend for TTM, an investor can discern the pace of business scaling, which for the biopharmaceutical company Rapport Therapeutics, Inc. (RAPP) signifies the commercialization efficiency of neurological developments while maintaining strict compliance with sanitary waste disposal regulations.